Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares OutstandingShares Outstanding
Ratios

Addex Therapeutics (ADXN) Receivables - Net (2018 - 2025)

Addex Therapeutics' Receivables - Net history spans 8 years, with the latest figure at $25132.2 for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 41.92% to $25132.2 in Q4 2025 year-over-year; TTM through Dec 2025 was $25132.2, a 41.92% increase, with the full-year FY2025 number at $24227.5, up 36.81% from a year prior.
  • Receivables - Net came in at $25132.2 for Q4 2025, down from $64064.4 in the prior quarter.
  • The five-year high for Receivables - Net was $647893.3 in Q2 2024, with the low at $17708.4 in Q4 2024.
  • Historically, Receivables - Net has averaged $224597.2 across 5 years, with a median of $193663.5 in 2021.
  • Biggest five-year swings in Receivables - Net: skyrocketed 390.85% in 2022 and later plummeted 92.83% in 2025.
  • Year by year, Receivables - Net stood at $178709.7 in 2021, then surged by 142.14% to $432725.4 in 2022, then plummeted by 71.25% to $124416.0 in 2023, then plummeted by 85.77% to $17708.4 in 2024, then surged by 41.92% to $25132.2 in 2025.
  • Business Quant data shows Receivables - Net for ADXN at $25132.2 in Q4 2025, $64064.4 in Q3 2025, and $46430.1 in Q2 2025.